Source: Thomas P. et Breast Cancer Treat. Res 2014 April; 144 (2): 427 - 435 (Ahern): al.Although preclinical evidence supports the anti-tum
Source: Thomas P. et Breast Cancer Treat. Res 2014 April; 144 (2): 427 - 435 (Ahern): al.
Although preclinical evidence supports the anti-tumor effects of cardiac glycosides, epidemiological studies have shown a higher risk of breast cancer in women who have been treated with digoxin. In this study, the nurses health study cohort assessed the relationship between digoxin use and breast cancer risk.
From 1994 to 2010, a total of 90202 postmenopausal women were enrolled in the study. Cox regression model was used to estimate the association between the use of digoxin and breast cancer, and the hormone receptor (ER) status and other risk factors of breast cancer were analyzed.
During the study, there were 5004 women who had been treated with digoxin, of whom, 144 had breast cancer. Women who were treated with digoxin were more likely than women to receive mammography screening, postmenopausal hormone replacement therapy, and other medications. The two groups had a similar history of birth and alcohol consumption. The results showed that digoxin was associated with a 45% increased risk of breast cancer in women over the age of 4 years (HR = + 1.45, with a confidence interval of 1.13-1.86:). The association was stronger in ER positive breast cancer (HR = 1.46, confidence interval: 1.10-1.95) than in ER negative breast cancer (HR = 1.12, 95% confidence interval: 0.52-2.37) (). After the correction of other risk factors, the relationship has not changed.
In this study, we conclude that the use of digoxin increases the risk of breast cancer in addition to other risk factors for breast cancer and screening measures. Digoxin, a common heart drug worldwide, may promote the development of breast cancer.